62.5 units of tirzepatide Weight-Loss Health Assessment 2.5mg (25 Units) Per Week Tirzepatide: The Game-Changer for Weight

The PIONEER PLUS trial showed superior glycemic control and body weight loss and improvement in the cardiometabolic risk factor profile with higher doses of once-daily oral semaglutide at 25 mg and 50 mg per day compared with the currently approved 14 mg dose for people with type 2 diabetes, said Vanita R

Instead of waiting for future oral GLP-1 entrants or potential price reductions, plans need to rethink and restructure their approach now

Gastroenterology | ACG

This is why medical supervision is critical

The study demonstrated a clear benefit for semaglutide, with a 24% lower risk to reach the primary outcome in the semaglutide group versus the placebo group

Alongside the elevated risk of acute pancreatitis, no significant differences were identified in the 1-year risk of pancreatic cancer between GLP-1 RA Users and NonGLP-1 RA Users